IDH2 and glioblastoma: While cases of GBM with mutations in IDH1 and IDH2 have significantly better clinical outcomes in terms of progression-free survival and overall survival than their IDH-wildtype counterparts, the vast majority of these patients still die from their disease within 5 years, and “long-term survival” is often defined as survival ≥ 36 months [31].